Redcliffe Labs expands footprint with investment in Bengaluru’s Celara Diagnostics

New Delhi: Redcliffe Labs has announced an investment in Celara Diagnostics, a prominent integrated diagnostic chain based in Bengaluru.

This move marks Redcliffe’s first strategic investment following a successful Series C funding round, which raised $42 million from notable investors, including Denmark’s Investment Fund for Developing Countries (IFU), LeapFrog Investments, HealthQuad, and Spark Growth Ventures.

With over 80 labs and more than 2,000 collection centers across 220 cities in India, Redcliffe Labs is well-positioned in the diagnostic sector. The company also provides home collection services supported by a workforce of over 1,000 phlebotomists. The newly acquired funds are aimed at expanding Redcliffe’s network of labs and collection centers, as well as enhancing its home collection services. The company has previously made acquisitions in north-western India and continues to pursue a pan-India expansion strategy through partnerships and strategic investments.

Celara Diagnostics, founded by Dr. Radhesh S. and Dr. Rekha Radhesh, operates a state-of-the-art 20,000 square foot facility in Bengaluru, specializing in high-end radiology and pathology services. The diagnostic chain also offers consultative super specialty services in neurology, cardiology, pulmonology, and more. This partnership is expected to provide Redcliffe Labs with valuable synergies as it seeks to strengthen its presence in the southern market, particularly in Bengaluru.

Wodehouse Capital Advisors served as the exclusive financial advisor to Celara Diagnostics, marking yet another transaction in the “Diagnostic & Pathology” vertical of its healthcare practice.